Mallia to Present sCD83’s Potential for Supporting Hair Transplantation at the FUE Europe Meeting in Madrid
|
EQS-News: Mallia Innovations
/ Key word(s): Conference
Mallia to Present sCD83’s Potential for Supporting
Erlangen, Germany, September 17, 2025 – Mallia Aesthetics GmbH, a company focusing on the development and commercialization of cosmetic products to stimulate hair growth, today announced that it will attend the 13thAnnual FUE Europe Meeting and give an oral presentation on the potential benefits of the soluble protein CD83 (sCD83) to support hair follicle growth in the context of hair transplant surgery. The FUE Meeting will take place from September 18 to 19, 2025, in Madrid, Spain and is organized by the European Organization of Hair Restoration Professionals. The conference focuses on transplant surgery using FUE, Follicular Unit Extraction, one of the most advanced methods of hair transplantation, and brings together hair transplant experts and representatives of related industries from all over the world. The oral presentation on sCD83, titled “Soluble CD83 as a Novel Approach for Potent Stimulation of Human Hair Follicles and Improved Wound Healing”, is scheduled on Friday, September 19, at 15:45 CET. Prof. Dr. Alexander Steinkasserer, Co-founder and Managing Director of Mallia, will showcase his team’s research on sCD83’s immunomodulatory properties, which have been shown to activate the growing phase of human hair follicles and promote wound healing. Combined, these effects can promote new hair growth and increased hair thickness. sCD83 was first described in 2001 by Prof. Steinkasserer and his team at the Department of Immune Modulation of Friedrich-Alexander University in Erlangen,1 and he later reported its therapeutic potential in wound healing and hair growth induction in 2022.2 Based on this scientific discovery, Mallia´s R&D team has developed MAL-838, a proprietary variant of sCD83. Mallia will introduce two complementary hormone-free product lines using MAL-838 to stimulate hair growth in Q4 2025. The 8T3 ProLine Follicle Booster developed for use by professionals in a medical-aesthetic setting, is designed to support hair follicles during hair transplantation procedures. The second 8T3 ProLine product, 8T3 ProLine Follicle Care & Protect Spray, has been developed to support wound healing after transplantation. In parallel, Mallia’s 8T3 Essentials line will bring hormone-free cosmetic solutions directly to consumers, starting with two topical products: 8T3 Essentials Hair Serum and 8T3 Essentials Lash & Brow Serum. Two consumer studies with the 8T3 Essentials products are underway to further substantiate their effects. Prof. Steinkasserer, Co-founder and Managing Director of Mallia, said: “The FUE Europe Meeting brings together exactly the specialists who will benefit from our upcoming 8T3 ProLine, developed to support hair follicles during and after transplantation. At the same time, it offers us the chance to share the scientific data and reasoning behind our product developments, which build on years of research into sCD83 and underline our commitment to making science-driven solutions accessible.” Mallia is proud to support the meeting as Platinum Sponsor. Alongside the scientific presentation, the booth will highlight the 8T3 ProLine and offer an opportunity for direct discussions with the management team.
About sCD83 Soluble CD83 (sCD83) is an immunomodulatory protein that is currently being developed for the topical treatment of hair loss (MAL‑856) and stimulation of hair growth (MAL‑838). The soluble CD83 protein was first identified in 2001 by Mallia co-founder Prof. Steinkasserer. It has anti-inflammatory properties via the induction of resolution of inflammation, which promotes wound healing and induces new hair growth.2 In addition, sCD83 has been shown to activate regulatory T cells (Tregs)3, which interact directly with hair follicles and can activate them.4 Furthermore, sCD83 inhibits cell death of hair follicles and directly activates follicular stem cells, as well as keratin production, thereby stimulating new hair growth. This multimodal mode of action distinguishes sCD83 from other topically applied hair growth agents. Topically applied, sCD83 can directly reach the hair follicles but does not penetrate through the skin and thus does not enter the bloodstream. The effect is localized, which is a major advantage over systemic treatment options, which can cause severe side effects. About hair loss Hormone-related hair loss in men and women (androgenetic alopecia, or AGA) is the most common form of hair loss. Worldwide, more than 70% of men and 50% of women post menopause are affected by androgenetic alopecia. Another 147 million people suffer from immune-related, circular hair loss (alopecia areata, or AA5,6). Androgenetic alopecia usually progresses gradually and is due to genetic and hormonal factors. In men, it often leads to a receding hairline and baldness on the top of the head, while in women it causes thinning hair in the parting area. Alopecia areata causes circular hair loss on the scalp, face or other parts of the body. It occurs when the immune system erroneously attacks hair follicles, leading to immune-mediated hair loss. About Mallia Mallia Innovations GmbH, based in Erlangen, Germany, is the holding company strategically driving the proprietary development and commercialization of biopharmaceutical therapies and cosmetic applications of the immunomodulatory sCD83 protein, targeting hair growth, hair loss and other dermatological indications, including wound healing. Mallia Therapeutics GmbH focuses on the clinical development of novel therapies for patients suffering from androgenetic alopecia or alopecia areata, among other conditions. MAL-856 is based on the scientifically proven immunomodulatory mode of action of sCD83, which has been investigated for close to 25 years by Mallia Co‑founder Prof. Dr Alexander Steinkasserer.1 Mallia Aesthetics GmbH focuses on cosmetic applications for the stimulation of hair growth, which are also based on the scientifically validated sCD83 protein. The Company develops Innovative cosmetic products using MAL-838 that will be marketed to specialists and consumers. For more information, visit www.mallia.com and follow us on LinkedIn.
1 Lechmann, M., Krooshoop, D. J., Dudziak, D., Kremmer, E., Kuhnt, C., Figdor, C. G., ... & Steinkasserer, A. (2001). The extracellular domain of CD83 inhibits dendritic cell–mediated T cell stimulation and binds to a ligand on dendritic cells. The Journal of experimental medicine, 194(12), 1813-1821. DOI: 10.1084/jem.194.12.1813 2 Royzman, D., Peckert-Maier, K., Stich, L., König, C., Wild, A. B., Tauchi, M., ... & Steinkasserer, A. (2022). Soluble CD83 improves and accelerates wound healing by the induction of pro-resolving macrophages. Frontiers in Immunology, 13, 1012647. DOI: 10.3389/fimmu.2022.1012647 3 Bock, F., Rössner, S., Onderka, J., Lechmann, M., Pallotta, M. T., Fallarino, F., ... & Zinser, E. (2013). Topical application of soluble CD83 induces IDO-mediated immune modulation, increases Foxp3+ T cells, and prolongs allogeneic corneal graft survival. The Journal of Immunology, 191(4), 1965-1975. DOI: 10.4049/jimmunol.1201531 4 Ali, N., Zirak, B., Rodriguez, R. S., Pauli, M. L., Truong, H. A., Lai, K., ... & Rosenblum, M. D. (2017). Regulatory T cells in skin facilitate epithelial stem cell differentiation. Cell, 169(6), 1119-1129. DOI: 10.1016/j.cell.2017.05.002 5 Feinstein, R. P. (2022). Androgenetic alopecia.: https://emedicine.medscape.com/article/1070167-overview 6 Mostaghimi, A., Gandhi, K., Done, N., Ray, M., Gao, W., Carley, C., ... & Sikirica, V. (2022). All-cause health care resource utilization and costs among adults with alopecia areata: A retrospective claims database study in the United States. Journal of Managed Care & Specialty Pharmacy, 28(4), 426-434: DOI: 10.18553/jmcp.2022.28.4.426
17.09.2025 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group. |
2198272 17.09.2025 CET/CEST
